CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 05/14/2026

CASI vs. CDT, APRE, KPRX, CALC, and MTEX

Should you buy CASI Pharmaceuticals stock or one of its competitors? MarketBeat compares CASI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CASI Pharmaceuticals include CDT Equity (CDT), Aprea Therapeutics (APRE), Kiora Pharmaceuticals (KPRX), CalciMedica (CALC), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.

How does CASI Pharmaceuticals compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

CDT Equity has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

CDT Equity has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

CDT Equity has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CDT Equity had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for CDT Equity and 0 mentions for CASI Pharmaceuticals. CDT Equity's average media sentiment score of 1.89 beat CASI Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Very Positive
CASI Pharmaceuticals	Neutral

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CASI Pharmaceuticals beats CDT Equity on 9 of the 15 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

CASI Pharmaceuticals (NASDAQ:CASI) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Aprea Therapeutics had 8 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 8 mentions for Aprea Therapeutics and 0 mentions for CASI Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.69 beat CASI Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Aprea Therapeutics	Positive

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

CASI Pharmaceuticals has a net margin of -183.93% compared to Aprea Therapeutics' net margin of -4,405.59%. CASI Pharmaceuticals' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Aprea Therapeutics	-4,405.59%	-97.54%	-75.40%

Aprea Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Aprea Therapeutics	$290K	39.62	-$12.60M	-$1.54	N/A

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 338.22%. Given CASI Pharmaceuticals' higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aprea Therapeutics beats CASI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Kiora Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.72 beat CASI Pharmaceuticals' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Kiora Pharmaceuticals	Positive

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, indicating that its share price is 148% less volatile than the broader market.

Kiora Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.71	N/A

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 295.26%. Given CASI Pharmaceuticals' higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kiora Pharmaceuticals beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to CalciMedica?

CASI Pharmaceuticals (NASDAQ:CASI) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, CalciMedica had 6 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 6 mentions for CalciMedica and 0 mentions for CASI Pharmaceuticals. CalciMedica's average media sentiment score of 0.98 beat CASI Pharmaceuticals' score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
CalciMedica	Positive

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,364.13%. Given CASI Pharmaceuticals' higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than CalciMedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CalciMedica has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CalciMedica	N/A	-1,093.51%	-144.33%

CalciMedica has lower revenue, but higher earnings than CASI Pharmaceuticals. CalciMedica is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CASI Pharmaceuticals beats CalciMedica on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Mannatech?

Mannatech (NASDAQ:MTEX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

In the previous week, Mannatech had 4 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Mannatech and 0 mentions for CASI Pharmaceuticals. Mannatech's average media sentiment score of 0.15 beat CASI Pharmaceuticals' score of 0.00 indicating that Mannatech is being referred to more favorably in the media.

Company	Overall Sentiment
Mannatech	Neutral
CASI Pharmaceuticals	Neutral

CASI Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mannatech has a net margin of -14.08% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-14.08%	-398.35%	-45.63%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Mannatech has higher revenue and earnings than CASI Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$8.00	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

13.0% of Mannatech shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CASI Pharmaceuticals beats Mannatech on 9 of the 16 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55M	$2.99B	$6.23B	$12.35B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-0.07	18.06	20.41	25.39
Price / Sales	0.10	257.99	541.58	73.15
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.73	4.31	9.83	6.93
Net Income	-$39.26M	$72.19M	$3.56B	$333.88M
7 Day Performance	N/A	-2.33%	0.52%	0.03%
1 Month Performance	N/A	-2.64%	-0.71%	1.93%
1 Year Performance	-88.54%	41.06%	36.34%	33.14%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	1.1214 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
CDT CDT Equity	0.439 of 5 stars	$2.08 -1.0%	N/A	-99.8%	$10.11M	N/A	N/A	3	Gap Up
APRE Aprea Therapeutics	4.1469 of 5 stars	$0.84 +0.3%	$4.10 +386.2%	-38.5%	$10.10M	N/A	N/A	7	Earnings Report Analyst Forecast Gap Down
KPRX Kiora Pharmaceuticals	2.3821 of 5 stars	$2.51 -1.2%	$10.00 +298.4%	-16.5%	$9.91M	$16.02M	N/A	10	Earnings Report
CALC CalciMedica	2.8356 of 5 stars	$0.60 +2.8%	$13.00 +2,061.3%	-64.5%	$9.47M	N/A	N/A	30	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. CDT, APRE, KPRX, CALC, and MTEX

How does CASI Pharmaceuticals compare to CDT Equity?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Summary

How does CASI Pharmaceuticals compare to Kiora Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to CalciMedica?

Summary

How does CASI Pharmaceuticals compare to Mannatech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. CDT, APRE, KPRX, CALC, and MTEX

How does CASI Pharmaceuticals compare to CDT Equity?

Is CDT or CASI more profitable?

Which has more volatility & risk, CDT or CASI?

Which has preferable valuation and earnings, CDT or CASI?

Do analysts prefer CDT or CASI?

Does the media favor CDT or CASI?

Do institutionals & insiders have more ownership in CDT or CASI?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Does the media refer more to CASI or APRE?

Which has more volatility & risk, CASI or APRE?

Is CASI or APRE more profitable?

Which has higher earnings & valuation, CASI or APRE?

Do insiders and institutionals have more ownership in CASI or APRE?

Do analysts rate CASI or APRE?

Summary

How does CASI Pharmaceuticals compare to Kiora Pharmaceuticals?

Does the media prefer CASI or KPRX?

Which has more risk & volatility, CASI or KPRX?

Is CASI or KPRX more profitable?

Which has better earnings and valuation, CASI or KPRX?

Do institutionals and insiders have more ownership in CASI or KPRX?

Do analysts recommend CASI or KPRX?

Summary

How does CASI Pharmaceuticals compare to CalciMedica?

Which has more risk & volatility, CASI or CALC?

Does the media prefer CASI or CALC?

Do analysts recommend CASI or CALC?

Is CASI or CALC more profitable?

Which has better earnings and valuation, CASI or CALC?

Do institutionals and insiders have more ownership in CASI or CALC?

Summary

How does CASI Pharmaceuticals compare to Mannatech?

Which has more volatility and risk, MTEX or CASI?

Does the media prefer MTEX or CASI?

Do analysts recommend MTEX or CASI?

Is MTEX or CASI more profitable?

Which has preferable valuation & earnings, MTEX or CASI?

Do institutionals and insiders hold more shares of MTEX or CASI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools